Global and Regional Companion Diagnostics

Companion Diagnostics Comprehensive Study by End-users (Pharma Companies, Reference Laboratories, CRO, Others), Product & Service (Assay kits & Reagents, Software & Services), Technology Type (Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH) , Next-generation Sequencing, Other), Indication (Cardiovascular, Neurological Diseases, Cancer, Infectious Diseases, Others) Players and Region - Global Market Outlook to 2027

Companion Diagnostics Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 14.6%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Companion Diagnostics Market Scope
Companion diagnostic is a medical device which provides information about safety and usefulness of a drug to be used as targeted medication. Essentially, this diagnostic is carried out to find patients who are expected to be benefited from a specific therapeutic product. Additionally, it monitors individual’s response to a treatment in order to find out it particular treatment is to be continued or it needs to be changed during course of time.

According to AMA, the Global Companion Diagnostics market is expected to see growth rate of 14.6%

Research Analyst at AMA estimates that American Players will contribute to the maximum growth of Global Companion Diagnostics market throughout the predicted period.

F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies Inc. (United States), Qiagen N.V. (Germany), Thermo Fisher Scientific Inc. (United States), Abbott Laboratories Inc. (United States), Biomérieux SA (France), Danaher Corporation (United States), Illumina Inc. (United States), Myriad Genetics (United States), Arup Laboratories Inc. (United States), Sysmex Corporation (Japan), Hologic Inc. (United States) and Novartis AG (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Almac Group (United Kingdom), Guardant Health, Inc. (United States), Almac Group (United Kingdom) and Abnova Corporation (Taiwan).

Segmentation Overview
The study have segmented the market of Global Companion Diagnostics market and Region with country level break-up.

On the basis of geography, the market of Companion Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Rise in Focus on Development of Personalized Medicine, Technical Advancement in Companion Diagnostics Devices and Increasing Focus on Liquid Biopsy

Market Growth Drivers:
Increasing Demand for Targeted Therapy Amid Increasing Prevalence of Chronic Disease and Rising in Number People with Cancer Diseases

Challenges:
Lack of Availability of Skilled Personnel

Restraints:
High Cost Associated with Companion Diagnostics Tests and Inadequate Reimbursement Scheme for Companion Diagnostics

Opportunities:
Rise in Demand of Next-Generation Sequencing (NGS) and Growing Number of Clinical Trials Globally




Key Target Audience
Companion Diagnostics Providers, End-user Industries, Potential Investors, Market Research and Consulting Firms, Governments and World Health Organization Bodies and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By End-users
  • Pharma Companies
  • Reference Laboratories
  • CRO
  • Others

By Product & Service
  • Assay kits & Reagents
  • Software & Services

By Technology Type
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH) 
  • Next-generation Sequencing
  • Other

By Indication
  • Cardiovascular
  • Neurological Diseases
  • Cancer
  • Infectious Diseases
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Demand for Targeted Therapy Amid Increasing Prevalence of Chronic Disease
      • 3.2.2. Rising in Number People with Cancer Diseases
    • 3.3. Market Challenges
      • 3.3.1. Lack of Availability of Skilled Personnel
    • 3.4. Market Trends
      • 3.4.1. Rise in Focus on Development of Personalized Medicine
      • 3.4.2. Technical Advancement in Companion Diagnostics Devices
      • 3.4.3. Increasing Focus on Liquid Biopsy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Companion Diagnostics, by End-users, Product & Service, Technology Type, Indication and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Companion Diagnostics (Value)
      • 5.2.1. Global Companion Diagnostics by: End-users (Value)
        • 5.2.1.1. Pharma Companies
        • 5.2.1.2. Reference Laboratories
        • 5.2.1.3. CRO
        • 5.2.1.4. Others
      • 5.2.2. Global Companion Diagnostics by: Product & Service (Value)
        • 5.2.2.1. Assay kits & Reagents
        • 5.2.2.2. Software & Services
      • 5.2.3. Global Companion Diagnostics by: Technology Type (Value)
        • 5.2.3.1. Polymerase Chain Reaction (PCR)
        • 5.2.3.2. Immunohistochemistry (IHC)
        • 5.2.3.3. In Situ Hybridization (ISH) 
        • 5.2.3.4. Next-generation Sequencing
        • 5.2.3.5. Other
      • 5.2.4. Global Companion Diagnostics by: Indication (Value)
        • 5.2.4.1. Cardiovascular
        • 5.2.4.2. Neurological Diseases
        • 5.2.4.3. Cancer
        • 5.2.4.4. Infectious Diseases
        • 5.2.4.5. Others
      • 5.2.5. Global Companion Diagnostics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Companion Diagnostics (Price)
  • 6. Companion Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Agilent Technologies Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Qiagen N.V. (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Thermo Fisher Scientific Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott Laboratories Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biomérieux SA (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Danaher Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Illumina Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Myriad Genetics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Arup Laboratories Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Sysmex Corporation (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Hologic Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Novartis AG (Switzerland)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Companion Diagnostics Sale, by End-users, Product & Service, Technology Type, Indication and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Companion Diagnostics (Value)
      • 7.2.1. Global Companion Diagnostics by: End-users (Value)
        • 7.2.1.1. Pharma Companies
        • 7.2.1.2. Reference Laboratories
        • 7.2.1.3. CRO
        • 7.2.1.4. Others
      • 7.2.2. Global Companion Diagnostics by: Product & Service (Value)
        • 7.2.2.1. Assay kits & Reagents
        • 7.2.2.2. Software & Services
      • 7.2.3. Global Companion Diagnostics by: Technology Type (Value)
        • 7.2.3.1. Polymerase Chain Reaction (PCR)
        • 7.2.3.2. Immunohistochemistry (IHC)
        • 7.2.3.3. In Situ Hybridization (ISH) 
        • 7.2.3.4. Next-generation Sequencing
        • 7.2.3.5. Other
      • 7.2.4. Global Companion Diagnostics by: Indication (Value)
        • 7.2.4.1. Cardiovascular
        • 7.2.4.2. Neurological Diseases
        • 7.2.4.3. Cancer
        • 7.2.4.4. Infectious Diseases
        • 7.2.4.5. Others
      • 7.2.5. Global Companion Diagnostics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Companion Diagnostics (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Companion Diagnostics: by End-users(USD Million)
  • Table 2. Companion Diagnostics Pharma Companies , by Region USD Million (2016-2021)
  • Table 3. Companion Diagnostics Reference Laboratories , by Region USD Million (2016-2021)
  • Table 4. Companion Diagnostics CRO , by Region USD Million (2016-2021)
  • Table 5. Companion Diagnostics Others , by Region USD Million (2016-2021)
  • Table 6. Companion Diagnostics: by Product & Service(USD Million)
  • Table 7. Companion Diagnostics Assay kits & Reagents , by Region USD Million (2016-2021)
  • Table 8. Companion Diagnostics Software & Services , by Region USD Million (2016-2021)
  • Table 9. Companion Diagnostics: by Technology Type(USD Million)
  • Table 10. Companion Diagnostics Polymerase Chain Reaction (PCR) , by Region USD Million (2016-2021)
  • Table 11. Companion Diagnostics Immunohistochemistry (IHC) , by Region USD Million (2016-2021)
  • Table 12. Companion Diagnostics In Situ Hybridization (ISH)  , by Region USD Million (2016-2021)
  • Table 13. Companion Diagnostics Next-generation Sequencing , by Region USD Million (2016-2021)
  • Table 14. Companion Diagnostics Other , by Region USD Million (2016-2021)
  • Table 15. Companion Diagnostics: by Indication(USD Million)
  • Table 16. Companion Diagnostics Cardiovascular , by Region USD Million (2016-2021)
  • Table 17. Companion Diagnostics Neurological Diseases , by Region USD Million (2016-2021)
  • Table 18. Companion Diagnostics Cancer , by Region USD Million (2016-2021)
  • Table 19. Companion Diagnostics Infectious Diseases , by Region USD Million (2016-2021)
  • Table 20. Companion Diagnostics Others , by Region USD Million (2016-2021)
  • Table 21. South America Companion Diagnostics, by Country USD Million (2016-2021)
  • Table 22. South America Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 23. South America Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 24. South America Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 25. South America Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 26. Brazil Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 27. Brazil Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 28. Brazil Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 29. Brazil Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 30. Argentina Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 31. Argentina Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 32. Argentina Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 33. Argentina Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 34. Rest of South America Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 35. Rest of South America Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 36. Rest of South America Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 37. Rest of South America Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 38. Asia Pacific Companion Diagnostics, by Country USD Million (2016-2021)
  • Table 39. Asia Pacific Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 40. Asia Pacific Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 41. Asia Pacific Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 42. Asia Pacific Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 43. China Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 44. China Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 45. China Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 46. China Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 47. Japan Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 48. Japan Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 49. Japan Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 50. Japan Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 51. India Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 52. India Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 53. India Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 54. India Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 55. South Korea Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 56. South Korea Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 57. South Korea Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 58. South Korea Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 59. Taiwan Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 60. Taiwan Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 61. Taiwan Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 62. Taiwan Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 63. Australia Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 64. Australia Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 65. Australia Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 66. Australia Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 70. Rest of Asia-Pacific Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 71. Europe Companion Diagnostics, by Country USD Million (2016-2021)
  • Table 72. Europe Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 73. Europe Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 74. Europe Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 75. Europe Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 76. Germany Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 77. Germany Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 78. Germany Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 79. Germany Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 80. France Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 81. France Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 82. France Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 83. France Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 84. Italy Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 85. Italy Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 86. Italy Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 87. Italy Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 88. United Kingdom Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 89. United Kingdom Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 90. United Kingdom Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 91. United Kingdom Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 92. Netherlands Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 93. Netherlands Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 94. Netherlands Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 95. Netherlands Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 96. Rest of Europe Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 97. Rest of Europe Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 98. Rest of Europe Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 99. Rest of Europe Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 100. MEA Companion Diagnostics, by Country USD Million (2016-2021)
  • Table 101. MEA Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 102. MEA Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 103. MEA Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 104. MEA Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 105. Middle East Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 106. Middle East Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 107. Middle East Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 108. Middle East Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 109. Africa Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 110. Africa Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 111. Africa Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 112. Africa Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 113. North America Companion Diagnostics, by Country USD Million (2016-2021)
  • Table 114. North America Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 115. North America Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 116. North America Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 117. North America Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 118. United States Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 119. United States Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 120. United States Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 121. United States Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 122. Canada Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 123. Canada Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 124. Canada Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 125. Canada Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 126. Mexico Companion Diagnostics, by End-users USD Million (2016-2021)
  • Table 127. Mexico Companion Diagnostics, by Product & Service USD Million (2016-2021)
  • Table 128. Mexico Companion Diagnostics, by Technology Type USD Million (2016-2021)
  • Table 129. Mexico Companion Diagnostics, by Indication USD Million (2016-2021)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Companion Diagnostics: by End-users(USD Million)
  • Table 144. Companion Diagnostics Pharma Companies , by Region USD Million (2022-2027)
  • Table 145. Companion Diagnostics Reference Laboratories , by Region USD Million (2022-2027)
  • Table 146. Companion Diagnostics CRO , by Region USD Million (2022-2027)
  • Table 147. Companion Diagnostics Others , by Region USD Million (2022-2027)
  • Table 148. Companion Diagnostics: by Product & Service(USD Million)
  • Table 149. Companion Diagnostics Assay kits & Reagents , by Region USD Million (2022-2027)
  • Table 150. Companion Diagnostics Software & Services , by Region USD Million (2022-2027)
  • Table 151. Companion Diagnostics: by Technology Type(USD Million)
  • Table 152. Companion Diagnostics Polymerase Chain Reaction (PCR) , by Region USD Million (2022-2027)
  • Table 153. Companion Diagnostics Immunohistochemistry (IHC) , by Region USD Million (2022-2027)
  • Table 154. Companion Diagnostics In Situ Hybridization (ISH)  , by Region USD Million (2022-2027)
  • Table 155. Companion Diagnostics Next-generation Sequencing , by Region USD Million (2022-2027)
  • Table 156. Companion Diagnostics Other , by Region USD Million (2022-2027)
  • Table 157. Companion Diagnostics: by Indication(USD Million)
  • Table 158. Companion Diagnostics Cardiovascular , by Region USD Million (2022-2027)
  • Table 159. Companion Diagnostics Neurological Diseases , by Region USD Million (2022-2027)
  • Table 160. Companion Diagnostics Cancer , by Region USD Million (2022-2027)
  • Table 161. Companion Diagnostics Infectious Diseases , by Region USD Million (2022-2027)
  • Table 162. Companion Diagnostics Others , by Region USD Million (2022-2027)
  • Table 163. South America Companion Diagnostics, by Country USD Million (2022-2027)
  • Table 164. South America Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 165. South America Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 166. South America Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 167. South America Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 168. Brazil Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 169. Brazil Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 170. Brazil Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 171. Brazil Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 172. Argentina Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 173. Argentina Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 174. Argentina Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 175. Argentina Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 176. Rest of South America Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 177. Rest of South America Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 178. Rest of South America Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 179. Rest of South America Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 180. Asia Pacific Companion Diagnostics, by Country USD Million (2022-2027)
  • Table 181. Asia Pacific Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 182. Asia Pacific Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 183. Asia Pacific Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 184. Asia Pacific Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 185. China Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 186. China Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 187. China Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 188. China Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 189. Japan Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 190. Japan Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 191. Japan Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 192. Japan Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 193. India Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 194. India Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 195. India Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 196. India Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 197. South Korea Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 198. South Korea Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 199. South Korea Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 200. South Korea Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 201. Taiwan Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 202. Taiwan Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 203. Taiwan Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 204. Taiwan Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 205. Australia Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 206. Australia Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 207. Australia Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 208. Australia Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 209. Rest of Asia-Pacific Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 210. Rest of Asia-Pacific Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 211. Rest of Asia-Pacific Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 212. Rest of Asia-Pacific Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 213. Europe Companion Diagnostics, by Country USD Million (2022-2027)
  • Table 214. Europe Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 215. Europe Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 216. Europe Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 217. Europe Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 218. Germany Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 219. Germany Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 220. Germany Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 221. Germany Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 222. France Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 223. France Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 224. France Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 225. France Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 226. Italy Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 227. Italy Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 228. Italy Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 229. Italy Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 230. United Kingdom Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 231. United Kingdom Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 232. United Kingdom Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 233. United Kingdom Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 234. Netherlands Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 235. Netherlands Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 236. Netherlands Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 237. Netherlands Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 238. Rest of Europe Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 239. Rest of Europe Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 240. Rest of Europe Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 241. Rest of Europe Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 242. MEA Companion Diagnostics, by Country USD Million (2022-2027)
  • Table 243. MEA Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 244. MEA Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 245. MEA Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 246. MEA Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 247. Middle East Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 248. Middle East Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 249. Middle East Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 250. Middle East Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 251. Africa Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 252. Africa Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 253. Africa Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 254. Africa Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 255. North America Companion Diagnostics, by Country USD Million (2022-2027)
  • Table 256. North America Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 257. North America Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 258. North America Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 259. North America Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 260. United States Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 261. United States Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 262. United States Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 263. United States Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 264. Canada Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 265. Canada Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 266. Canada Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 267. Canada Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 268. Mexico Companion Diagnostics, by End-users USD Million (2022-2027)
  • Table 269. Mexico Companion Diagnostics, by Product & Service USD Million (2022-2027)
  • Table 270. Mexico Companion Diagnostics, by Technology Type USD Million (2022-2027)
  • Table 271. Mexico Companion Diagnostics, by Indication USD Million (2022-2027)
  • Table 272. Research Programs/Design for This Report
  • Table 273. Key Data Information from Secondary Sources
  • Table 274. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Companion Diagnostics: by End-users USD Million (2016-2021)
  • Figure 5. Global Companion Diagnostics: by Product & Service USD Million (2016-2021)
  • Figure 6. Global Companion Diagnostics: by Technology Type USD Million (2016-2021)
  • Figure 7. Global Companion Diagnostics: by Indication USD Million (2016-2021)
  • Figure 8. South America Companion Diagnostics Share (%), by Country
  • Figure 9. Asia Pacific Companion Diagnostics Share (%), by Country
  • Figure 10. Europe Companion Diagnostics Share (%), by Country
  • Figure 11. MEA Companion Diagnostics Share (%), by Country
  • Figure 12. North America Companion Diagnostics Share (%), by Country
  • Figure 13. Global Companion Diagnostics share by Players 2021 (%)
  • Figure 14. Global Companion Diagnostics share by Players (Top 3) 2021(%)
  • Figure 15. Global Companion Diagnostics share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2021
  • Figure 19. Agilent Technologies Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Agilent Technologies Inc. (United States) Revenue: by Geography 2021
  • Figure 21. Qiagen N.V. (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Qiagen N.V. (Germany) Revenue: by Geography 2021
  • Figure 23. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2021
  • Figure 25. Abbott Laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott Laboratories Inc. (United States) Revenue: by Geography 2021
  • Figure 27. Biomérieux SA (France) Revenue, Net Income and Gross profit
  • Figure 28. Biomérieux SA (France) Revenue: by Geography 2021
  • Figure 29. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Danaher Corporation (United States) Revenue: by Geography 2021
  • Figure 31. Illumina Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Illumina Inc. (United States) Revenue: by Geography 2021
  • Figure 33. Myriad Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 34. Myriad Genetics (United States) Revenue: by Geography 2021
  • Figure 35. Arup Laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Arup Laboratories Inc. (United States) Revenue: by Geography 2021
  • Figure 37. Sysmex Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 38. Sysmex Corporation (Japan) Revenue: by Geography 2021
  • Figure 39. Hologic Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Hologic Inc. (United States) Revenue: by Geography 2021
  • Figure 41. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 43. Global Companion Diagnostics: by End-users USD Million (2022-2027)
  • Figure 44. Global Companion Diagnostics: by Product & Service USD Million (2022-2027)
  • Figure 45. Global Companion Diagnostics: by Technology Type USD Million (2022-2027)
  • Figure 46. Global Companion Diagnostics: by Indication USD Million (2022-2027)
  • Figure 47. South America Companion Diagnostics Share (%), by Country
  • Figure 48. Asia Pacific Companion Diagnostics Share (%), by Country
  • Figure 49. Europe Companion Diagnostics Share (%), by Country
  • Figure 50. MEA Companion Diagnostics Share (%), by Country
  • Figure 51. North America Companion Diagnostics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • F. Hoffmann-La Roche AG (Switzerland)
  • Agilent Technologies Inc. (United States)
  • Qiagen N.V. (Germany)
  • Thermo Fisher Scientific Inc. (United States)
  • Abbott Laboratories Inc. (United States)
  • Biomérieux SA (France)
  • Danaher Corporation (United States)
  • Illumina Inc. (United States)
  • Myriad Genetics (United States)
  • Arup Laboratories Inc. (United States)
  • Sysmex Corporation (Japan)
  • Hologic Inc. (United States)
  • Novartis AG (Switzerland)
Additional players considered in the study are as follows:
Almac Group (United Kingdom) , Guardant Health, Inc. (United States) , Almac Group (United Kingdom) , Abnova Corporation (Taiwan)
Select User Access Type

Key Highlights of Report


Sep 2022 231 Pages 72 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global and Regional Companion Diagnostics Quantitative research analysis
Global and Regional Companion Diagnostics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Companion Diagnostics study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Companion Diagnostics Market is gaining popularity and expected to see strong valuation by 2027 .
According to AMA, the Global Companion Diagnostics market is expected to see growth rate of xx%.
The Companion Diagnostics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global and Regional Companion Diagnostics Report?

Have a Query? Click Here

Other Related Reports

Vaccines & Vaccination Comprehensive Study by Type (Monovalent Vaccines, Multivalent Vaccines), Application (Pediatrics disease, Adults disease), Route of Administration (Intramuscular and Subcutaneo...
$ 3750
Dog Calcium Supplement Comprehensive Study by Application (Households, Veterinary Hospitals, Pet Cannels, Other), Form (Powder, Paste, Liquid, Capsules, Other), Distribution Channel (Online, Offline)...
$ 3800
Quinine Sulphate Comprehensive Study by Application (Malaria, Problematic Leg Cramps, Other), Distribution Chanel (Online, Offline), Dose (200mg, 300mg, Other) Players and Region - Global Market Outl...
$ 3500
Ear Drops Comprehensive Study by Type (Antibiotic Ear Drops, Corticosteroid Ear Drops, Antifungal Ear Drops, Acidic Ear Drops), Application (Adult, Children), Composition (Ciprofloxacin, Dexamethason...
$ 3650
Peptide Synthesis Equipment Comprehensive Study by Type (Peptide Synthesizers, Chromatography Equipment, Lyophilizers), Application (Pharmaceutical and Biotechnology Companies , Contract Development ...
$ 3750
Antibody-drug Conjugates Comprehensive Study by Type (Monoclonal Antibody, Potent Cytotoxic Agent, Linker, Others), Application (Leukemia, Glioblastoma, Lymphoma, Others), Product Type (Adcertis, Kad...
$ 3750